Who are cephalexin, or levofloxacin, or clindamycin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Fetroja, Zerbaxa, Teflaro, Cefditoren Pivoxyl, Omnicef, Maxipime.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/cephalexin-or-levofloxacin-or-clindamycin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

cephalexin, or levofloxacin, or clindamycin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

cephalexin, or levofloxacin, or clindamycin (cephalexin, or levofloxacin, or clindamycin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: cephalosporin. Area: Infectious Disease.

phase 3 cephalosporin penicillin-binding proteins (PBPs) Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

cephalexin, or levofloxacin, or clindamycin (cephalexin, or levofloxacin, or clindamycin) — Vanderbilt University Medical Center. Cephalexin is a beta-lactam antibiotic that inhibits cell wall synthesis in bacteria.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
cephalexin, or levofloxacin, or clindamycin TARGET	cephalexin, or levofloxacin, or clindamycin	Vanderbilt University Medical Center	phase 3	cephalosporin	penicillin-binding proteins (PBPs)
Fetroja	CEFIDEROCOL	Shionogi	marketed	Cephalosporin Antibacterial		2019-01-01
Zerbaxa	CEFTOLOZANE	Cubist Pharms	marketed	Cephalosporin Antibacterial		2014-01-01
Teflaro	CEFTAROLINE FOSAMIL	AbbVie	marketed	Cephalosporin Antibacterial		2010-01-01
Cefditoren Pivoxyl	CEFDITOREN PIVOXIL	Vansen Pharma	marketed	Cephalosporin Antibacterial		2001-01-01
Omnicef	CEFDINIR		marketed	Cephalosporin Antibacterial [EPC]		1997-01-01
Maxipime	CEFEPIME	Baxter	marketed	Cephalosporin Antibacterial		1996-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2028-05-15 — Zerbaxa · 7129232 · US
2032-09-07 — Zerbaxa · 10028963 · US
2032-09-07 — Zerbaxa · 9724353 · US
2032-09-27 — Zerbaxa · 8476425 · US
2032-09-27 — Zerbaxa · 8685957 · US
2034-03-14 — Zerbaxa · 10420841 · US
2034-03-14 — Zerbaxa · 11278622 · US
2034-03-14 — Zerbaxa · 8968753 · US
2034-03-14 — Zerbaxa · 9320740 · US
2034-03-14 — Zerbaxa · 9872906 · US
2034-05-28 — Zerbaxa · 8906898 · US
2034-09-09 — Zerbaxa · 10376496 · US
2034-09-09 — Zerbaxa · 10933053 · US
2035-08-14 — Zerbaxa · 10125149 · US

Sponsor landscape (cephalosporin class)

Vanderbilt University Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). cephalexin, or levofloxacin, or clindamycin — Competitive Intelligence Brief. https://druglandscape.com/ci/cephalexin-or-levofloxacin-or-clindamycin. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab